Clinical trials: completed, sponsored by UNC Lineberger Comprehensive Cancer Center
Cervix Carcinoma, Cervical Squamous Cell Carcinoma
Hybrid PET/MR in the Therapy of Cervical Cancer
This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals.
- Conditions
- Cervix Carcinoma, Cervical Squamous Cell Carcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT01759355
- Testing
- FDG PET/MR
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hematopoietic Stem Cell Transplantation, Delirium
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including health-related quality of life…
- Conditions
- Hematopoietic Stem Cell Transplantation, Delirium, Thiamine Deficiency
- Trial name
- NCT03263442
- Testing
- Thiamine, Normal saline
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Bladder Cancer
Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer
The purpose of this study is to create a registry of older patients undergoing surgical and/or medical treatment for bladder cancer.
- Trial name
- PORCH (NCT01776138)
- Testing
- Collect Blood and Survey Instruments
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Get REAL and HEEL Research Program
The UNC Get REAL \& HEEL (GR\&H) program has provided after treatment support for women with a breast cancer diagnosis since 2006.
- Trial name
- NCT03760536
- Testing
- 16-week Exercise Rehabilitation Program for Breast Cancer Survivors
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
Overweight and obese endometrial cancer (EC) survivors at the University of North Carolina (UNC) at Chapel Hill will be approached for tailored feedback fitness intervention.
- Trial name
- MOVES (NCT03820024)
- Testing
- Tailored Feedback Messages
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Squamous Cell of Head and Neck
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy…
- Trial name
- NCT02585973
- Testing
- AZD1775, Cisplatin, Intensity Modulated Radiotherapy Treatments
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neurofibromatosis-1, Optic Glioma
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibromatosis-1 (NF1) associated…
- Conditions
- Neurofibromatosis-1, Optic Glioma, Plexiform Neurofibroma
- Trial name
- NCT01800032
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Castration-resistant Prostate Cancer, Androgen Deprivation Therapy
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
This single arm, multi-site pilot study aims to evaluate the feasibility of recruiting and adherence to a 12 week home-based exercise intervention to be conducted in men with metastatic castration resistant prostate cancer…
- Trial name
- NCT03672396
- Testing
- Home-based exercise
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Physical Activity, Neoplasms
Promoting Physical Activity in Young Adult Cancer Survivors Using mHealth and Adaptive Tailored Feedback Strategies
To date, few interventions have been designed specifically to promote physical activity in young adult cancer survivors, nor used novel technologies for delivery; none have been successful in promoting long-term adherence to PA.
- Conditions
- Physical Activity, Neoplasms, Neoplasms by Site, Cancer
- Trial name
- IMPACT (NCT03569605)
- Testing
- Self-help, Intervention
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Sarcoma
PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas
Purpose: To assess the utility of PET/MR in assessing response to neoadjuvant radiation therapy in the treatment of high grade sarcomas.
- Trial name
- NCT03076333
- Testing
- PET/MR
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Rectal Carcinoma
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
- Trial name
- NCT01751516
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Myeloid Leukemia
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
Purpose: The purpose of this trial is to investigate whether a microfluidics assay can detect trace amounts of residual leukemia and predict relapse in acute myeloid leukemia (AML) patients in remission who have undergone…
- Trial name
- NCT03488862
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non Small Cell Lung Cancer
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Progression free survival after locally ablative therapy and erlotinib in EGFR patients progressed after EGFR-TKI therapy
- Trial name
- NCT01573702
- Testing
- Stereotactic Radiosurgery, Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Renal Cell Carcinoma
Imaging Correlates of Renal Cell Carcinoma Biological Features
This pilot study is designed to evaluate imaging parameters indicative of underlying tumor biology. Patients with large renal masses (>3 cm, or at the discretion of the investigator) who are planning to undergo nephrectomy will…
- Trial name
- NCT01665703
- Testing
- FDG PET/MR
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Kaposi Sarcoma, HIV
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes.
- Trial name
- NCT03160183
- Where
- 2 sites in Malawi
- Volunteers
- 157 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Neoplasm of Lung, Decision Support Techniques
Effect of Incidental Findings Information on Lung Cancer Screening Intent
This online randomized controlled trial seeks to determine if inclusion of incidental findings information in a lung cancer screening decision aid affects screening intent among screening-eligible individuals.
- Conditions
- Neoplasm of Lung, Decision Support Techniques, Mass Screening
- Trial name
- NCT04432753
- Testing
- Lung Cancer Screening Decision Aid with Incidental Findings Information, Lung Cancer Screening Decision Aid without Incidental Findings Information
- Where
- United States
- Volunteers
- 419 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cigarette Smoking Behavior
Enhancing Source Credibility in Tobacco Regulatory Communications
This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial.
- Trial name
- NCT03339206
- Testing
- Constituent message with FDA and quitline, Constituent message without FDA and quitline, Littering message (Control)
- Where
- United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
- Trial name
- NCT01412229
- Testing
- Cetuximab, Nab-paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Stage III Melanoma, Stage IV Melanoma
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
This phase II study in 20 patients with BRAFV600E mutant, unresectable stage III/IV melanoma is designed to explore the mechanisms by which tumors acquire resistance to the combination of a BRAF inhibitor (dabrafenib) and MEK…
- Conditions
- Stage III Melanoma, Stage IV Melanoma, Unresectable Melanoma, BRAF Mutant Melanoma
- Trial name
- NCT01726738
- Testing
- BRAF inhibitor dabrafenib and MEK inhibitor trametinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center